Napa Extend extended-release tablets are formulated with Paracetamol BP 665 mg, renowned for its efficacy in relieving prolonged pain caused by osteoarthritis and muscle discomfort, including backaches. This medication also offers effective and temporary relief from various other painful conditions, such as headaches, tension headaches, menstrual cramps, toothaches, post-dental procedure pain, as well as cold and flu-related discomfort. Additionally, Napa Extend extended-release tablets effectively aid in reducing fever. With its unique composition, this medication addresses a wide range of pain-related issues, ensuring long-lasting relief and improved well-being.
Paracetamol, known as Acetaminophen, is an analgesic and antipyretic medication with minimal anti-inflammatory properties. It primarily acts on the central nervous system, increasing the pain threshold by inhibiting the activity of cyclooxygenase enzymes (COX-1, COX-2, and COX-3) responsible for prostaglandin production. Derived from para aminophenol, Paracetamol exhibits analgesic, antipyretic, and anti-inflammatory effects. Widely recognized as a commonly used and safe pain reliever, Paracetamol works quickly without the numerous adverse effects associated with aspirin.
Dosage guidelines for different formulations of Paracetamol are as follows:
Dosage for children varies based on age:
Dosage for children and adults varies based on age:
Dosage for children:
This Paracetamol formulation with Actizorb technology dissolves up to five times faster than standard tablets. It provides fast-acting and safe pain relief with notable antipyretic properties. It is particularly suitable for individuals who cannot tolerate aspirin or other analgesics.
It is contraindicated in known hypersensitivity to Paracetamol.
Instances of adverse reactions are infrequent. While there have been reports of the following reactions, a definite link between Paracetamol administration and these effects has not been established: dyspepsia, nausea, and allergic and hematological responses.
Extended use of Paracetamol may require reduced anticoagulant dosage. Concurrent use of medications affecting gastric emptying can influence Paracetamol absorption. Metoclopramide may reduce absorption in a sustained release form. Paracetamol can increase chloramphenicol concentrations. The risk of Paracetamol toxicity is higher with enzyme-inducing agents like alcohol or anticonvulsant drugs.
Exercise caution when administering Paracetamol to patients with hepatic or renal impairment. Patients who are also taking medications known to cause liver damage should use Paracetamol with care. It is important to advise patients against simultaneous use of other products containing Paracetamol. Only use this medication as prescribed and when absolutely necessary for the intended patient.
Paracetamol falls under Category A, indicating its extensive use by pregnant women and women of childbearing age without any evidence of an elevated risk in birth defects or any direct or indirect adverse effects on the developing fetus.
Paracetamol is detectable in breast milk, but the amount available for the infant’s intake has been reported to be less than 0.1% of a 500 mg dose and between 0.04 to 0.23% of a single 650 mg dose, based on immediate-release formulations. There is no available data on the excretion of sustained release Paracetamol in breast milk. However, it is unlikely that Paracetamol 665 mg extended-release tablets would significantly increase the excretion of Paracetamol in breast milk, as this product is designed to maintain rather than elevate plasma concentrations compared to immediate-release formulations. Normal maternal intake of Paracetamol as a pain reliever does not appear to pose any risk to the breastfed infant.
Keep in a dry location below 30°C. Ensure it is safely stored away from children’s access.
The package includes 120 extended release tablets arranged in blister strips of 12X10. Each individual extended release tablet contains 665 mg of Paracetamol BP.